Uzm. Dr. Hakan Taban

Eğitim ve Uzmanlık

• 2006-2012 Marmara Üniversitesi Tıp Fakültesi İngilizce Lisans
  
• 2013-2017 Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı
  
• 2018-2022 Hacettepe Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı Yan Dal Uzmanlık
  

Deneyim

• 2012-2013 Kandıra Ecz. M. Kazım Dinç Hastanesi Acil Servis Hekimi
  
• 2018-2018 Gercüş Devlet Hastanesi İç Hastalıkları Uzmanı
  
• 2022-2024 Samsun Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanı
  

Kurs ve Sertifikalar

• 2020 ESMO Virtual Congress
  
• 2021 İstinye Üniversitesi Sürekli Eğitim Merkezi İyi Klinik Uygulamalar Sertifikası
  
• 2022 20th Western Europe Masterclass in Medical Oncology İspanya
  
• 2022 Tıbbi Onkoloji Yeterlilik Belgesi Türk Tıbbi Onkoloji Derneği 
  
• 2023 ESMO Examination Certificate Avrupa Medikal Onkoloji Derneği Yeterlilik Belgesi
  

Mesleki Üyelikler

• 2018 Türk Tıbbi Onkoloji Derneği
  
• 2019 Onkoloji ve İmmünoterapi Derneği
  
• 2019 European Society for Medical Oncology
  
• 2020 European School of Oncology

Ödüller

• 2020 - 10th International Gastrointestinal Cancers Virtual Conference 2-6 December A rare metastasis case: BRAF V600 Mutation Positive Gastrointestinal Stromal Tumor with Breast Metastasis (En iyi poster ödülü)
• 2022 - 20th Western Europe Masterclass in Medical Oncology, İspanya (Ölçme ve değerlendirme testi 1.’lik ödülü
• 2022 – Türk Tıbbi Onkoloji Derneği, Tıbbi Onkoloji Yeterlilik Belgesi (3.’lük ödülü)
• 2023 – ESMO Examination Certificate (En yüksek performans gösterenler listesi)

Araştırma ve Yayınlar

• 2020 - 7th International Multidisciplinary Good Medical Research Congress and Good Oncology Research Conference October 24-31, 2020 / Virtual Oral Presentation: Enzalutamide Single Center Experience in Metastatic Castration-Resistant Prostate Cancer
• 2021 - 11th International Gastrointestinal Cancer Conference December 2 - 5, 2021, Istanbul                  Oral Presentation: Evaluation of the impact of preoperative sarcopenia  on treatment results and survival in patients with pancreatic cancer
• 2021 - 11th International Gastrointestinal Cancer Conference December 2 - 5, 2021, Istanbul                  Oral Presentation: Evaluation of gastrointestinal cancer patients  radiologically-diagnosed with sinusoidal obstruction syndrome: Single-Center Experience
• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Aktas BY, Taban H, Aksoy S. N Engl J Med. 2019 Mar 7;380(10):985-986. doi: 10.1056/NEJMc1900150.                                                                 
• Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design. Guven DC, Guner G, Aktas BY, Aktepe OH, Taban H, Arik Z. Clin Colorectal Cancer. 2020 Sep;19(3):e71-e72. doi: 10.1016/j.clcc.2020.02.011. Epub 2020 Mar 6.
• Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH, Aksu NM, Akkaş M, Erman M, Kilickap S, Dizdar O, Aksoy S. Support Care Cancer. 2020 Aug 26. doi: 10.1007/s00520-020-05702-8. Online ahead of print.    
• The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Bilgin B, Taban H, Kucukarda A, Erturk I, Hızal M, Yıldız B, Yıldırım N, Demirci U, Sendur MA, Utkan G, Kılıckap S, Cicin I, Karadurmus N, Ürün Y. J Oncol Pharm Pract. 2020 Jul;26(5):1110-1116. doi: 10.1177/1078155219883004. Epub 2019 Oct 25.
• Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Hizal M, Sendur MA, Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Taban H, Kucukarda A, Erturk I, Bilgin B, Yıldırım N, Demirci U, Kılıckap S, Cicin I, Karadurmus N, Yalcin B, Ürün Y. J Oncol Pharm Pract. 2020 Oct;26(7):1583-1589. doi: 10.1177/1078155219900908. Epub 2020 Feb 13.                                                                             
• Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer. C Guven D, Kilickap S, Guner G, Taban H, Dizdar O. J Oncol Pharm Pract. 2020 Jan;26(1):256-258. doi: 10.1177/1078155219877234. Epub 2019 Sep 29.
• PILE: a candidate prognostic score in cancer patients treated with immunotherapy. Guven DC, Yildirim HC, Bilgin E, Aktepe OH, Taban H, Sahin TK, Cakir IY, Akin S, Dizdar O, Aksoy S, Yalcin S, Erman M, Kilickap S. Clin Transl Oncol. 2021 Aug;23(8):1630-1636. doi: 10.1007/s12094-021-02560-6. Epub 2021 Feb 14. PMID: 33586122.
• Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors. Guven DC, Aktepe OH, Taban H, Aktas BY, Guner G, Yildirim HC, Sahin TK, Aksun MS, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. Biomark Med. 2021 Sep;15(13):1123-1130. doi: 10.2217/bmm-2020-0674. Epub 2021 Aug 16. PMID: 34397271.
• Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma. Aktepe OH, Güner G, Güven DC, Taban H, Yıldırım HÇ, Şahin TK, Ardıç FS, Yeter HH, Yüce D, Erman M. Turk J Urol. 2021 Mar;47(2):113-119. doi: 10.5152/tud.2021.20377. Epub 2021 Mar 1. PMID: 33819441; PMCID: PMC8018802.
• Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, Arıkan R, Arslan Ç, Taban H, Küçükarda A, Öztaş NŞ, Sever ÖN, Uçar G, Can O, Şendur MA, Demirci U, Kılıçkap S, Çiçin İ, Öksüzoğlu B, Özgüroğlu M, Ürün Y. Future Oncol. 2021 Dec;17(35):4861-4869. doi: 10.2217/fon-2021-0717. Epub 2021 Nov 2. PMID: 34726480.
• Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Guven DC, Aksun MS, Sahin TK, Aktepe OH, Yildirim HC, Taban H, Ceylan F, Kertmen N, Arik Z, Dizdar O, Kilickap S, Aksoy S, Yalcin S, Erman M. Support Care Cancer. 2021 Sep;29(9):5417-5423. doi: 10.1007/s00520-021-06139-3. Epub 2021 Mar 11. PMID: 33709186.
• Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Guven DC, Taban H, Dizdar O. J Oncol Pharm Pract. 2022 Jan;28(1):203-204. doi: 10.1177/10781552211045909. Epub 2021 Oct 9. PMID: 34628993.
• Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience. Diker O, Aktas BY, Ak R, Koylu B, Bas O, Taban H, Guven DC, Olgun P, Kertmen N, Dizdar O, Oksuzoglu B, Aksoy S. Future Oncol. 2022 Jan;18(3):323-331. doi: 10.2217/fon-2021-0303. Epub 2021 Nov 11. PMID: 34758639.
• Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report. Taban H, Guven DC, Kılıçkap S. Cureus. 2022 Aug 9;14(8):e27828. doi: 10.7759/cureus.27828. PMID: 36106272; PMCID: PMC9452052
• Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. Yildirim HC, Guven DC, Aktepe OH, Taban H, Yilmaz F, Yasar S, Aksoy S, Erman M, Kilickap S, Yalcin S. J Clin Med. 2022 Sep 1;11(17):5171. doi: 10.3390/jcm11175171. PMID: 36079101; PMCID: PMC9457309.
• Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience. Demir M, Güven D, Aktaş BY, Güner G, Aktepe OH, Taban H, Karakaş Y, Kılıçkap S, Kars A, Türker A, Dizdar Ö. South Asian J Cancer. 2022 Nov 14;11(4):287-292. doi: 10.1055/s-0042-1755467. eCollection 2022 Oct. PMID: 36756104
• The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients. Özdede M, Taban H, Akman O, Önder S, Kılıçkap S. Cureus. 2023 Aug 24;15(8):e44016. doi: 10.7759/cureus.44016. eCollection 2023 Aug. PMID: 37746394
• Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer. Ceylan F, Guven DC, Taban H, Aktepe O, Sahin TK, Kilickap S, Turker A, Hamaloglu E, Karakoc D, Isik A, Akyol A, Yalcin S, Dizdar O. Clin Res Hepatol Gastroenterol. 2023 Mar;47(3):102091. doi: 10.1016/j.clinre.2023.102091. Epub 2023 Feb 3. PMID: 36738855
• Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer. Efil SC, Guner G, Guven DC, Celikten B, Celebiyev E, Taban H, Akyol A, Isik A, Kilickap S, Yalcin S, Dizdar O. Clin Res Hepatol Gastroenterol. 2023 Aug;47(7):102171. doi: 10.1016/j.clinre.2023.102171. Epub 2023 Jun 21. PMID: 37352926